
Commentary|Videos|September 13, 2024
Dr Jonasch on the Preliminary Efficacy of NKT-2152 in Advanced ccRCC
Author(s)Eric Jonasch, MD
Fact checked by: Ashling Wahner , Kristi Rosa
Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.
Advertisement
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses preliminary findings from an ongoing phase 1/2 trial (NCT05119335) investigating the HIF-2α inhibitor NKT-2152 in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC), as well as the potential clinical implications of these data.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































